MASH (Metabolic Dysfunction-Associated Steatohepatitis) is the most severe form of fatty liver disease, characterised by the accumulation of fat in the liver alongside inflammation and liver cell damage. If left untreated, it can progress to liver scarring, cirrhosis, liver failure, or liver cancer.
Globally,
fatty liver disease affects more than 115 million people, a number that continues to grow due to rising rates of obesity and type 2 diabetes, two primary risk factors for the condition. For many, it significantly impacts their ability to work, focus, and enjoy daily life.
Current treatments can be ineffective or carry side effects, and not all options are suitable for long-term use. This trial is testing a new once-daily investigational tablet that targets liver disease and damage associated with MASH, offering new hope for those who haven't found relief with existing therapies.
